evaluate the pharmaceuticals company ozempic on glp-1 and insurance providers Access Gap: Mapping Who Can Actually Afford America's Miracle Weight-Loss Drugs Perspectives from employers on the
Description
Oezer, K
New injectable GLP-1s are advancing through clinical trials, with CagriSema (cagrilintide/semaglutide) among the most advanced, showing greater weight loss than semaglutide and expected to seek approval in late 2025

always verify current standing independently

We don't

Natalicchio, A., & Perrini, S
[DOI] [PubMed] [Google Scholar] 58.Han S.O., Kommaddi R.P., Shenoy S.K
